Wedekind, Dirk

[["dc.bibliographiccitation.firstpage","831"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Neural Transmission"],["dc.bibliographiccitation.lastpage","837"],["dc.bibliographiccitation.volume","107"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:09:47Z"],["dc.date.available","2018-11-07T11:09:47Z"],["dc.date.issued","2000"],["dc.description.abstract","Background. Research on basal HPA axis activity in patients with panic disorder showed inconsistent results. Methods. Basal total plasma, plasma free and salivary cortisol levels were compared in patients with panic disorder (n = 47) and in healthy individuals (n = 23). Correlations between these fractions were calculated. Results. All three basal cortisol fractions were significantly elevated in patients compared to controls. There were significant correlations between all three cortisol fractions. Conclusions. Nonsignificant differences between cortisol levels of patients and healthy controls in previous studies may have been due to inclusion of less severely ill patients or to small sample sizes (96 words)."],["dc.identifier.doi","10.1007/s007020070062"],["dc.identifier.isi","000088415100008"],["dc.identifier.pmid","11005547"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53083"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0300-9564"],["dc.title","Salivary, total plasma and plasma free cortisol in panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","163"],["dc.bibliographiccitation.volume","257"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Fentzahn, Evelyn"],["dc.contributor.author","Truemper, Patricia"],["dc.contributor.author","Ruether, Eckart"],["dc.date.accessioned","2018-11-07T11:03:29Z"],["dc.date.available","2018-11-07T11:03:29Z"],["dc.date.issued","2007"],["dc.description.abstract","Background To date, specific scales for the assessment of severity of somatoform disorders are still rare. Characteristic cognitive and behavioural domains, representing severity are not incorporated in the existing scales. Results with the novel quantification inventory for somatoform syndromes (QUISS) are presented in this paper. Methods The QUISS has been developed as a qualified severity scale for patients fulfilling diagnostic criteria according to DSM-IV or/and ICD-10. It was designed to be particularly suitable for application in clinical trials and for monitoring the efficacy of psychotherapy and pharmacotherapy. Not only number, severity and frequency of somatoform symptoms, but also common cognitive and behavioural domains of somatoform disorders have been included into this instrument. Both an 18-item patient- and observer-rated version are available taking about 20 min to complete. The questionnaire was applied to patients with somatoform disorder (N = 96), major depression (N = 24), and panic disorder (N = 16). Results The psychometric properties of the scale are satisfactory. The QUISS showed high objectivity (Cronbach's alpha = 0.90 for both versions; inter-scale correlations r = 0.64-0.88; p < 0.05), good test-retest- (r = 0.87; p < 0.05) and inter-rater-reliability (r = 0.89; p < 0.05). External validity (moderately high correlations of QUISS-T to SOMS 7T (r = 0.54), significant discrimination to major depression p < 0.05) was satisfactory. Factor structure revealed five relevant factors. Conclusions The QUISS could be a useful instrument in somatoform disorders for the assessment of syndrome severity and treatment outcome in scientific and clinical settings."],["dc.identifier.doi","10.1007/s00406-006-0700-4"],["dc.identifier.isi","000246262900005"],["dc.identifier.pmid","17203236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51628"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0940-1334"],["dc.title","The quantification inventory for somatoform syndromes MISS): a novel instrument for the assessment of severity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","175"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","187"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Seidler-Brandler, Ulrich"],["dc.contributor.author","Becker, Andreas"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Ruether, Eckart"],["dc.date.accessioned","2018-11-07T11:07:40Z"],["dc.date.available","2018-11-07T11:07:40Z"],["dc.date.issued","2007"],["dc.description.abstract","Background. A number of meta-analyses have led to contradictory results regarding the efficacy of the psychological and pharmacological treatment of anxiety disorders. The main reasons for these inconsistent results seem to be the inclusion of heterogeneous studies and influences of selection biases. We performed a meta-analysis, which only included studies using a direct comparison of pharmacological, psychological, or combined treatments. Method. Sixteen studies on panic disorder, six studies on social anxiety disorder, and two studies on generalized anxiety disorder have been analyzed. Effect sizes for differences between the different treatment modalities were calculated. Also, the effect sizes of the pre-post differences were calculated. Results. Pharmacological treatment, cognitive-behavioural treatment, and the combination of both treatment modalities all led to substantial improvement between pre- and post-treatment. Combined pharmacological and psychological treatment was superior to the monotherapies for panic disorder. For social anxiety disorder, there is only preliminary support for combined treatment. Due to lack of sufficient data, no final conclusions can be drawn for generalized anxiety disorder. Conclusions. While drug treatment and CBT showed equal efficacy, only in panic disorder the combination of pharmacological and psychological treatment was superior to either treatment alone. For the other anxiety disorders, the evidence for greater efficacy of combination treatment is still not sufficient due to lack of studies."],["dc.identifier.doi","10.1080/15622970601110273"],["dc.identifier.isi","000249360400003"],["dc.identifier.pmid","17654408"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52620"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Ltd"],["dc.relation.issn","1562-2975"],["dc.title","Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","169"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Psychiatry Research"],["dc.bibliographiccitation.lastpage","179"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Krause, Jan"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:08:29Z"],["dc.date.available","2018-11-07T11:08:29Z"],["dc.date.issued","2005"],["dc.description.abstract","Patients with borderline personality disorder (BPD) were have not yet been compared with a healthy control group with regard to traumatic life events during childhood. The patients (n = 66) and controls (n = 109) were investigated using a comprehensive retrospective interview with 203 questions about childhood traumatic life events, parental attitudes, family history of psychiatric disorders and birth risk factors. The frequency of reports of traumatic childhood experiences was significantly higher in patients than in controls, including sexual abuse, violence, separation from parents, childhood illness, and other factors. On a 0- to 10-point \"severe trauma scale,\" patients had significantly more severe traumatic events (mean score = 3.86, SD = 1.77) than control subjects (0.61, SD = 0.93). Only four (6.1%) of the BPD patients, but 67 (61.5%) of the controls did not report any severe traumatic events at all. Compared with controls, patients described the attitude of their parents as significantly more unfavorable in all aspects. Patients reported significantly higher rates of psychiatric disorders in their families in general, especially anxiety disorders, depression, and suicidality. Among birth risk factors, premature birth was reported more often in BPD subjects. In a logistic regression model of all possible etiological factors examined, the following factors showed a significant influence: familial neurotic spectrum disorders, childhood sexual abuse, separation from parents and unfavorable parental rearing styles. The present data support the hypothesis that the etiology of BPD is multifactorial and that familial psychiatric disorders and sexual abuse are contributing factors. © 2005 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.psychres.2003.07.008"],["dc.identifier.isi","000228935500007"],["dc.identifier.pmid","15840418"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52793"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0165-1781"],["dc.title","Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","31"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","MMW - Fortschritte der Medizin"],["dc.bibliographiccitation.lastpage","34"],["dc.bibliographiccitation.volume","148"],["dc.contributor.author","Bandelow, B."],["dc.contributor.author","Wolff-Menzler, C."],["dc.contributor.author","Wedekind, D."],["dc.contributor.author","Rüther, E."],["dc.date.accessioned","2021-06-01T10:49:00Z"],["dc.date.available","2021-06-01T10:49:00Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1007/BF03364531"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86128"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1613-3560"],["dc.relation.issn","1438-3276"],["dc.title","Wie lange muss mindestens behandelt werden?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","259"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Fortschritte der Neurologie · Psychiatrie"],["dc.bibliographiccitation.lastpage","267"],["dc.bibliographiccitation.volume","73"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:03:23Z"],["dc.date.available","2018-11-07T11:03:23Z"],["dc.date.issued","2005"],["dc.description.abstract","Subjects with personality disorders represent a relevant subset of the clinical psychiatric population and, to an even bigger extent, a comorbid condition to an axis-I diagnosis. Personality disorders appear to be difficult to treat and problematic in the therapeutic setting, and a pharmacologic treatment often does not follow recommendations from empirical studies. Psychopharmacologic drugs are able to modify the expression of certain personality dimensions, which are mainly disorder-related variables of temperament. Modern pharmacotherapy of personality disorders has a neurobiological basis. This is underlined by evidence from animal studies and can be associated with certain receptor-specific functions in humans. Treatment is consequently symptom-related and not specific for any disorder. It must be stressed that certain features but not the entire personality can be modified by drug treatment. Data from drug studies are still relatively scarce. An overview of studies on personality disorders is presented including information on dosages and augmenting strategies. Psychotherapy still is the basic treatment for personality disorders. However, psychopharmacological interventions should not only be considered when psychotherapy has failed. Treatments should be complementary from the start. There is a rationale for short- and long-term treatment. The latter is indicated, despite of the scarcity of data, when longer lasting and severe affective symptoms emerge. Response rates vary among the trials and appear to be lower than in non-comorbid axis-I disorders. A treatment algorithm is presented."],["dc.identifier.doi","10.1055/s-2004-830107"],["dc.identifier.isi","000229325200005"],["dc.identifier.pmid","15880304"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51604"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0720-4299"],["dc.title","Pharmacotherapy in personality disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","31"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","MMW-FORTSCHRITTE DER MEDIZIN"],["dc.bibliographiccitation.lastpage","34"],["dc.bibliographiccitation.volume","148"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Wolff-Menzler, Claus"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T10:25:47Z"],["dc.date.available","2018-11-07T10:25:47Z"],["dc.date.issued","2006"],["dc.description.abstract","Anxiety disorders show a tendency to become chronic. Behavioral treatment and pharmacotherapeutic measures must frequently be applied over a lengthy period of time. The most suitable drugs for long-term treatment are the selective serotonin reuptake inhibitors (SSRI) and the serotonin norepinephrine reuptake inhibitor (SNRI), venlafaxine. With regard to side effects,the specific characteristics of the anti-anxiety drugs used for long-term therapy must be taken into account."],["dc.identifier.isi","000235242200003"],["dc.identifier.pmid","27387313"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42924"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","1438-3276"],["dc.title","Anxiety disorders: Long-term treatment and relapse prevention"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","German Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","7"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Jacobs, Stefan"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Schneider, Udo"],["dc.contributor.author","Cimander, Konrad"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2019-07-10T08:13:27Z"],["dc.date.available","2019-07-10T08:13:27Z"],["dc.date.issued","2009"],["dc.description.abstract","Objective: Previous reports on heroin and cocaine addicts showed drug-related and gender differences in psychiatric comorbidity, which has relevant consequences for treatment. However, studies vary substantially with respect to methods and timeframes. Studies on German patient groups are scarce. Methods: Data on psychiatric and somatic comorbidity, substance addiction history, present intake patterns and sociodemography were obtained from 43 female (n=11) and male (n=32) heroin and cocaine addicts in acute inpatient detoxification treatment or specified long-term treatment. A European Addiction-Severity-Index (EuropASI) based centre questionnaire and the Mini-DIPS were applied. Results: Treatment groups did not differ in psychiatric comorbidity. Female subjects, however, had a significantly higher prevalence of psychiatric comorbid diagnoses (p<.05), mostly anxiety and affective disorders which significantly correlated with low occupational status (p<.05).Patients in long-term treatment abused more other substances and had an earlier onset of regular substance abuse (in particular alcohol and cannabis) (p<.05). Conclusion: Heroin and cocaine addicted females are more likely than males to have affective and anxiety disorders. Long-term treatment attenders appear to be more severely addicted (earlier onset and additional abuse) than acute treatment patients but do not differ in comorbidity. However, no axis-II diagnoses were recorded and the sample-size was small. Results should be regarded as preliminary (German J Psychiatry 2009; 12: 1-7)."],["dc.identifier.fs","541930"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5950"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61249"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1455-1033"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Psychiatric Comorbidity and Gender Effects in Heroin and Cocaine-Addicted Patients in Specified Long-Term Treatment and Acute Inpatient Detoxification Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","119"],["dc.bibliographiccitation.issue","2-3"],["dc.bibliographiccitation.journal","Neuropsychobiology"],["dc.bibliographiccitation.lastpage","122"],["dc.bibliographiccitation.volume","56"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Preiss, Birgit"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Ruether, Eckart"],["dc.contributor.author","Huether, Gerald"],["dc.contributor.author","Adler, Lothar"],["dc.date.accessioned","2018-11-07T11:07:14Z"],["dc.date.available","2018-11-07T11:07:14Z"],["dc.date.issued","2007"],["dc.description.abstract","Introduction: The aim of this naturalistic study was to gain more information about the elevation of basal hypothalamic-pituitary- adrenal (HPA) activity in relationship to symptom severity in specific subtypes of depressive episodes. Method: Hamilton Depression Rating Scale scores and aggregated nocturnal urinary cortisol excretion were measured in 4 groups of inpatients with depressive episodes (n = 48; monopolar nonpsychotic, monopolar psychotic, bipolar nonpsychotic and bipolar psychotic) at the beginning and at the end of inpatient treatment. Results: The initial elevation of nocturnal urinary cortisol excretion was most pronounced in psychotic patients. At the end of treatment, the Hamilton Depression Rating Scale scores had decreased significantly in all patients to comparable levels, whereas the nocturnal cortisol excretion values were still relatively elevated in mono- and bipolar psychotic patients compared to mono- and bipolar nonpsychotic ones. Conclusion: The observation that the basal HPA activity remains elevated even after remission of symptoms in patients with psychotic depression supports the concept that a dysfunctional regulation of the HPA system is possibly a trait- rather than a state-related feature. Copyright (c) 2008 S. Karger AG, Basel."],["dc.identifier.doi","10.1159/000112953"],["dc.identifier.isi","000253014500009"],["dc.identifier.pmid","18182828"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52509"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","0302-282X"],["dc.title","Relationship between nocturnal urinary cortisol excretion and symptom severity in subgroups of patients with depressive episodes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","164"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Meyer, T."],["dc.contributor.author","Opitz, M."],["dc.contributor.author","Bartmann, U."],["dc.contributor.author","Hillmer-Vogel, U."],["dc.contributor.author","George, A."],["dc.contributor.author","Pekrun, G."],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T10:39:09Z"],["dc.date.available","2018-11-07T10:39:09Z"],["dc.date.issued","2003"],["dc.description.abstract","Blunted neuroendocrine and physiological responses to the selective 5-HT1A receptor agonist, ipsapirone, have been observed in patients with panic disorder and/or agoraphobia (PDA). In order to examine whether this hyporesponsiveness to ipsapirone is modified by pharmacological or non-pharmacological therapeutic interventions, challenges with an oral dose of ipsapirone (0.3 mg/kg) and placebo were performed in patients with PDA before and after 10 weeks of treatment with clomipramine, aerobic exercise and placebo. Before treatment, administration of ipsapirone was followed by significant increases of cortisol, anxiety and other psychopathological symptoms in comparison to the placebo challenge. In addition, a significant decrease of body temperature was observed. After the 10-week treatment period, the psychological responses to ipsapirone were significantly reduced in the clornipramine and the exercise group. In contrast, there was a non-significant trend towards higher cortisol responses after clornipramine and exercise treatment. The hypothermic response to ipsapirone was significantly reduced by clornipramine treatment. In conclusion, our results demonstrate that effective treatment of panic disorder has divergent effects on the psychological, neuroendocrine and temperature responses to ipsapirone. (C) 2003 Elsevier Science B.V./ECNP All rights reserved."],["dc.identifier.doi","10.1016/S0924-977X(02)00177-3"],["dc.identifier.isi","000183090600003"],["dc.identifier.pmid","12729940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45977"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0924-977X"],["dc.title","5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]